Lercanidipina Tolife (Lercanidipine Hydrochloride)

Lercanidipine is a dihydropyridine calcium‑channel blocker indicated for the treatment of hypertension, where it helps achieve controlled blood pressure levels.

• Hypertension: reduction of elevated arterial pressure in patients with primary (essential) hypertension.
• Isolated systolic hypertension: lowering of systolic blood pressure in older adults with predominantly high systolic values.
• Secondary hypertension: adjunctive blood‑pressure control when other causes have been addressed.

• Lercanidipine selectively inhibits L‑type calcium channels in vascular smooth‑muscle cells, preventing calcium influx that is required for contraction. This leads to dose‑dependent vasodilation of peripheral arteries, decreasing systemic vascular resistance and consequently lowering arterial blood pressure without significant effect on cardiac contractility.

Lercanidipine may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

• Headache: mild to moderate intensity, often transient.
• Flushing: warmth and redness, usually short‑lived.
• Peripheral edema: swelling of ankles or feet.
• Dizziness or light‑headedness, especially after standing.
• Tachycardia: increased heart rate.
• Nausea or abdominal discomfort.

Serious or Rare Side Effects

• Severe hypotension: marked drop in blood pressure requiring medical attention.
• Myocardial infarction: rare occurrence in susceptible patients.
• Elevated liver enzymes: possible hepatic involvement.
• Allergic reactions: rash, pruritus, or urticaria.
• Angioedema: swelling of face, lips, or throat.
• Cardiac conduction abnormalities: heart block or arrhythmias.

Before initiating therapy with Lercanidipine, several safety considerations should be reviewed.

• Blood pressure monitoring: regularly assess to avoid excessive hypotension.
• Hepatic impairment: use with caution; dose adjustment may be required.
• Concomitant antihypertensives: evaluate for additive blood‑pressure lowering effects.
• Discontinuation: avoid abrupt cessation; taper if clinically indicated.
• Heart failure: monitor for fluid retention and worsening symptoms.
• Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Lercanidipine can interact with several drug classes, influencing its efficacy and safety.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma concentrations.
• Grapefruit juice: can markedly raise drug levels.
• Other calcium‑channel blockers: additive vasodilatory effect leading to hypotension.

Moderate Interactions (Monitor Closely):\n- Diuretics: may enhance blood‑pressure lowering effect.

• Beta‑blockers: combined use may require dose adjustments.
• ACE inhibitors or ARBs: monitor for excessive hypotension.
• Simvastatin high dose: increased risk of myopathy.